A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder

Phase 1

• Conditions: Obsessive-compulsive disorder (OCD); MedDRA version: 9.1Level: LLTClassification code 10029898Term: Obsessive-compulsive disorder

• Registration Number: EUCTR2008-006947-38-GB
• Lead Sponsor: King's College London (Institute of Pyschiatry)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07-09
• Last Update Posted: 4 December 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

i) DSM-IV diagnosis of OCD
ii) Age 12-18
iii) Referred to the National and Specialist OCD clinic at Maudsley Hospital
iv) If on medication, that should be stable for 12 weeks, and not be changed during the course of the trial
v) Provision of written informed consent (patient and carer)
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

i) Current diagnosis of psychosis, current alcohol or substance abuse/dependence
ii) English too poor to engage in treatment
iii) Severe disabling neurological disorder
iv) Medical contraindication to cycloserine, including epilepsy and porphyria
v) A diagnosed global learning disability or pervasive developmental disorder
vi) Characteristics interfering with completion of treatment eg life-threatening or unstable medical illness
vii) Pregnancy
viii) Not suitable for CBT (selective mutism, lack of insight or motivation to change)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified